Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 9 of 40 for:    CARBAMAZEPINE AND Valproic Acid

GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00567424
Recruitment Status : Withdrawn (No longer viable)
First Posted : December 5, 2007
Last Update Posted : April 4, 2013
Sponsor:
Information provided by:
GlaxoSmithKline

Brief Summary:
Study to determine drug interactions between GW273225 and the anticonvulsants valproate, carbamazepine or phenytoin

Condition or disease Intervention/treatment Phase
Epilepsy Drug: GW273225 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Evaluation of Drug Interactions, Safety, Tolerability and Efficacy of GW273225 Add-on Treatment of Partial Seizures, Whether or Not Secondarily Generalized
Study Start Date : July 2006
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2008

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Pharmacokinetic drug interactions with the most common inhibiting and inducing antiepileptic drugs AEDs: valproate(VPA), carbamazepine(CBZ) and phenytoin (PHT).

Secondary Outcome Measures :
  1. Safety/tolerability of GW273225 in adults with refractory epilepsy Efficacy of GW273225 in adults with refractory epilepsy Potential initial starting doses for a subsequent placebo-controlled dose-ranging Phase IIb study.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Confident diagnosis of epilepsy
  • Currently on VPA, CBZ or PHT
  • >or= 4 seizures/4 weeks prior to screen

Exclusion criteria:

  • Prior lamotrigine use (excluded if treatment discontinued for clinically significant safety reasons (i.e., rash, hypersensitivity)).
  • Females of childbearing potential on hormonal contraceptives or hormone replacement therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00567424


Locations
Layout table for location information
United States, Arizona
GSK Clinical Trials Call Center
Phoenix, Arizona, United States, 85054
GSK Clinical Trials Call Center
Sun City, Arizona, United States, 85351
United States, Arkansas
GSK Clinical Trials Call Center
Little Rock, Arkansas, United States, 72205
United States, California
GSK Clinical Trials Call Center
San Jose, California, United States, 95128
GSK Clinical Trials Call Center
Santa Monica, California, United States, 90404
United States, Florida
GSK Clinical Trials Call Center
Jacksonville, Florida, United States, 32209
GSK Clinical Trials Call Center
Tallahassee, Florida, United States, 32308
GSK Clinical Trials Call Center
Tampa, Florida, United States, 33613
United States, Illinois
GSK Clinical Trials Call Center
Chicago, Illinois, United States, 60612
GSK Clinical Trials Call Center
Springfield, Illinois, United States, 62704
United States, Iowa
GSK Clinical Trials Call Center
Iowa City, Iowa, United States, 52242
United States, Kansas
GSK Clinical Trials Call Center
Wichita, Kansas, United States, 67214
United States, Maryland
GSK Clinical Trials Call Center
Baltimore, Maryland, United States, 21287
United States, Massachusetts
GSK Clinical Trials Call Center
Boston, Massachusetts, United States, 02215
United States, Minnesota
GSK Clinical Trials Call Center
Rochester, Minnesota, United States, 55905
GSK Clinical Trials Call Center
St. Cloud, Minnesota, United States, 56303
United States, Missouri
GSK Clinical Trials Call Center
Springfield, Missouri, United States, 65804
GSK Clinical Trials Call Center
St. Louis, Missouri, United States, 63310
United States, New York
GSK Clinical Trials Call Center
Amherst, New York, United States, 14226
United States, North Carolina
GSK Clinical Trials Call Center
Durham, North Carolina, United States, 27560
United States, Ohio
GSK Clinical Trials Call Center
Cleveland, Ohio, United States, 44195
GSK Clinical Trials Call Center
Toledo, Ohio, United States, 43614
United States, Oregon
GSK Clinical Trials Call Center
Medford, Oregon, United States, 97504
GSK Clinical Trials Call Center
Portland, Oregon, United States, 97225
GSK Clinical Trials Call Center
Portland, Oregon, United States, 97239-3098
United States, Texas
GSK Clinical Trials Call Center
Dallas, Texas, United States, 75230
United States, Vermont
GSK Clinical Trials Call Center
Burlington, Vermont, United States, 05401
United States, Virginia
GSK Clinical Trials Call Center
Richmond, Virginia, United States, 23219
GSK Clinical Trials Call Center
Roanoke, Virginia, United States, 24018
United States, Washington
GSK Clinical Trials Call Center
Seattle, Washington, United States, 98104
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials, MD GlaxoSmithKline

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00567424    
Other Study ID Numbers: NEC107055
First Posted: December 5, 2007    Key Record Dates
Last Update Posted: April 4, 2013
Last Verified: April 2013
Keywords provided by GlaxoSmithKline:
epilepsy
refractory
seizure
drug interactions
pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Seizures
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms